New Formulations of GLP-1s Demonstrate Positive Results, Potentially Offering Additional Options for Obesity Medications
illi News/10304492

Trending...
CHICAGO, June 23, 2025 ~ New studies have revealed promising results for two medications, orfoglipron and MariTide, in the treatment of type 2 diabetes and obesity. The findings from the ACHIEVE-1 Trial and the MariTide Phase 2 Trial were simultaneously published in the New England Journal of Medicine (NEJM) and presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago.

According to recent statistics, more than 2 in 5 adults in the US are obese or severely obese, while an estimated 90 to 95% of over 38 million Americans with diabetes have type 2 diabetes. Glucagon-like peptide-1 (GLP-1) receptor agonists are a well-established treatment option for both conditions. However, there is a growing need for additional options that cater to patient preferences and provide tailored care, such as oral forms or injectables with less frequent dosing.

The MariTide Phase 2 Trial, which enrolled 592 adults, demonstrated weight loss and A1C reduction in both groups with and without type 2 diabetes. This trial evaluated MariTide, a novel long-acting GLP-1 receptor agonist and GIP receptor antagonist. Participants were assigned to different monthly fixed dose regimens or an every-8-week dose regimen. The results showed an average weight loss of up to approximately 20% in participants with obesity alone and a weight loss and A1C reduction of up to approximately 17% and 2.2%, respectively, in those with obesity and type two diabetes. Additionally, there were improvements in other cardiometabolic measures such as blood pressure and lipid levels. These positive outcomes suggest that MariTide has the potential to be a once-monthly treatment option for both conditions.

More on illi News
Dr. Ania M. Jastreboff, professor at Yale School of Medicine (Endocrinology) and director of the Y-Weight Yale Obesity Research Center, expressed her excitement about the potential of MariTide as a once-monthly treatment option for people with obesity. She stated, "Once-monthly treatment options for type 2 diabetes have long been sought after, yet elusive. MariTide has the potential to be a once-monthly treatment option for people with obesity, with and without type 2 diabetes, resulting in substantial weight reduction and robust improvements in glycemia."

The study also revealed that more than 90% of eligible participants have enrolled for an additional 52 weeks of the study (Part 2). This second part will evaluate the impact of MariTide on sustained weight loss with lower doses, less frequent dosing, or discontinuation and is expected to conclude later this year.

In another breakthrough study, the ACHIEVE-1 Trial demonstrated the safety and effectiveness of orfoglipron, the first oral small molecule non-peptide GLP-1 RA to successfully complete a Phase 3 trial. The trial enrolled 559 patients with type 2 diabetes who were not taking any glucose-lowering medications and had inadequate glycemic control across multiple countries. The results showed that orfoglipron significantly lowered A1C levels by an average rate of 1.3% to 1.6% across doses from a baseline of 8.0%. Additionally, participants experienced an average weight loss of 7.9% (roughly 16lbs) at the highest dose, with indications of further potential weight loss as they did not reach a plateau at the end of the study.

More on illi News
One significant advantage of orfoglipron is that it can be taken as a once-daily pill without any food or water restrictions. This contributed to approximately 73% of participants in the treatment regimen achieving their A1C target, with a potential increase up to 76%.

These groundbreaking studies provide hope for individuals with type 2 diabetes and obesity, as they offer new treatment options that can potentially lead to significant weight loss and improved glycemic control. The results of these trials have been published in prestigious medical journals and presented at a major scientific conference, highlighting their significance in the field of diabetes and obesity research.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on illi News